Sepracor Inc. – Annual Report

Sepracor Inc. – Annual Report

Following the successful launch of a new drug, Lunesta, the equity of Sepracor’s corporate brand and Lunesta’s identity were leveraged to theme this year’s annual report. Metamorphosis applies to many aspects of Sepracor’s business strategy. It defines their emergence as a full-fledged commercial pharma.